The University of Texas MD Anderson Cancer Center is one of the world’s largest and most respected centers devoted exclusively to cancer patient care, research, education and prevention.

The Texas Legislature created MD Anderson in 1941 as part of The University of Texas System. It is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971.

MD Anderson is ranked the No. 1 hospital for cancer care in the nation by U.S. News & World Report’s 2019–2020 “Best Hospitals” survey. Ever since the survey began in 1990, MD Anderson has ranked as one of the nation’s top two hospitals for cancer care.

#1 in cancer care
IN FY19:

- **148.7 K** patients
- **1.5 M** outpatient visits
- **$902.3 M** spent on research
- **1.5 M** outpatient visits
- **$238.6 M** donated care
- **$902.3 M** spent on research
- **$5.4 B** operating budget
- **1.4 K** clinical trials
- **7 K** trainees
- **21.7 K** employees
- **2.1 K** volunteers
At MD Anderson, everything we do revolves around our patients. In FY19, more than 148,700 people sought the superior care that has made MD Anderson so widely respected — 47,500 of whom were new patients. There were more than 11,600 patients enrolled in 1,360-plus clinical trials exploring innovative treatments. MD Anderson’s cancer clinical trial program is one of the largest of its kind.

**Clinical Activity FY19**

- Hospital admissions: 30,339
- Average number of inpatient beds: 678
- Outpatient clinic visits, treatments, procedures: 1,547,197
- Pathology/laboratory medicine procedures: 13,262,586
- Diagnostic imaging procedures: 615,053
- Surgeries: 20,900
- Total active clinical research protocols: 1,364
Noteworthy

• MD Anderson is accredited by the Joint Commission to ensure patients receive the best and safest health care possible. The nonprofit commission accredits more than 22,000 U.S. health care organizations and programs.

• MD Anderson has more full-time registered nurses and advanced practice providers specializing in oncology than most hospitals nationwide, and the most of any hospital in Texas, ensuring that patients receive the utmost attention and quality care.

• The nursing program holds the American Nurses Credentialing Center’s Magnet Nursing Services Recognition status. The Magnet program is recognized as the gold standard of nursing excellence, and recognizes health care organizations for quality patient care, nursing excellence and innovations in nursing practice.

• Every MD Anderson clinic has a team of physicians who are further specialized, each with a deep expertise in a particular form of cancer.

• Doctors at MD Anderson treat more rare cancers in a single day than most physicians see in a lifetime.

• MD Anderson’s Moon Shots Program® is a collaborative effort to quickly turn scientific discoveries into clinical advances that save patients’ lives. The program’s 13 Moon Shots are disease-focused initiatives targeting 20 types of cancer.

• So far, the Moon Shots Program has received $469 million in private philanthropic commitments.

• As part of the MD Anderson Oncology Program at Lyndon B. Johnson Hospital, a team of MD Anderson doctors provides cancer care to underserved Texans in collaboration with Harris Health System.
• MD Anderson provided more than $238.6 million in uncompensated cancer care in FY19.

• MD Anderson’s new Hemovigilance Unit opened in August 2019. Believed to be the first of its kind in the nation, the unit is home to specially trained registered nurses who provide real-time monitoring of patients at risk for potential blood transfusion reactions. Blood transfusions are the most common inpatient procedure at MD Anderson.

• The Adolescent and Young Adult Oncology Program supports cancer patients ages 15 to 29 with access to guidance and support services in the areas of genetics, oncofertility, psychosocial support and survivorship.

• MD Anderson’s Enhanced Recovery Program is an evidence-based approach that helps patients recover more quickly and with better outcomes after surgery.

• A volunteer workforce of 1,118 on-site, trained volunteers and 1,000 off-site myCancerConnection trained survivor volunteers contributed 120,431 hours of service in FY19.

• More than 30,000 patients chose to receive services at MD Anderson locations outside the Texas Medical Center – in West Houston, League City, Sugar Land and The Woodlands. These locations provide patients with comprehensive cancer care close to home, from screenings, to treatment, to survivorship. Patients have access to clinical trials and the renowned, high-quality multidisciplinary care which is the hallmark of MD Anderson. Each year, the number of patients seeking care at these locations steadily increases. Learn more at mdanderson.org/locations.
At MD Anderson, crucial scientific knowledge gained in the laboratory is rapidly translated into clinical care. In FY19, MD Anderson invested more than $902 million in research, a 16% increase in the past five years.

**Sources of Research Expenditures**

<table>
<thead>
<tr>
<th>Source</th>
<th>FY19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private industry grants and contracts</td>
<td>$156,234,119</td>
</tr>
<tr>
<td>Philanthropy and foundations</td>
<td>$164,633,426</td>
</tr>
<tr>
<td>State funding allocated for research</td>
<td>$74,137,278</td>
</tr>
<tr>
<td>Federal grants and contracts</td>
<td>$179,497,413</td>
</tr>
<tr>
<td>Internal funding allocated for research</td>
<td>$327,756,840</td>
</tr>
<tr>
<td><strong>Total research expenditures</strong></td>
<td><strong>$902,259,076</strong></td>
</tr>
</tbody>
</table>

**Noteworthy**

- The cancer center’s researchers conducted 1,364 clinical trials in FY19 that tested new drugs, new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments.

- In FY19, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded MD Anderson more than $44 million to attract top researchers and educators, to support lifesaving research and to enhance prevention efforts to eliminate cancer.
• More than $156 million in private industry grants and contracts and almost $165 million in philanthropic and foundation grants supported MD Anderson research projects.

• MD Anderson researchers developed a new type of immunotherapy called CAR NK cell therapy, which enhances the ability of natural killer (NK) cells to recognize and destroy cancer cells. In Nov. 2019, MD Anderson and Takeda Pharmaceutical Company announced a partnership to advance the treatment into clinical trials. The trials’ findings will determine whether CAR NK cell therapy will gain Food and Drug Administration approval.

• The new Brain Metastasis Clinic at MD Anderson is among the first of its kind. The clinic streamlines treatment for patients whose cancer has spread to the brain. In a single visit, patients see a team of specialists who develop a care plan and move the patient quickly into treatment.

• A first-of-its-kind study conducted at MD Anderson revealed that, when given prior to chemotherapy, a combination of three targeted therapies – rituximab, lenalidomide and ibrutinib – produced an 85% response rate in newly diagnosed patients with a specific type of diffuse large b-cell lymphoma.

• MD Anderson researchers found that adding the targeted therapy ribociclib to standard hormone treatments for young women with advanced breast cancer can reduce their risk of death by 29%.
• The difference between pancreatic cancer patients who survive long-term and those who do not is due in part to the bacteria on their tumors and in their digestive tracts, an MD Anderson study found. Pancreatic cancer is controlled longer in patients who have a more diverse array of bacteria or an abundance of certain types of bacteria, researchers found. The discovery raised the possibility of transplanting feces from a healthy donor into a pancreatic cancer patient to fight the disease.

• MD Anderson researchers discovered that a new drug called erdafitinib turns off a genetic mutation linked to rapid growth of tumor cells in bladder cancer patients. The trial led to the Food and Drug Administration’s approval of the drug for treating patients who carry the mutation.

• The Therapeutics Discovery team advanced two novel cancer treatments into Phase I clinical trials for a variety of cancer types. This unique group of clinicians, researchers and drug development experts operate a biotech-like engine within MD Anderson, working to develop life-saving transformational medicines to meet the needs of cancer patients.
MD Anderson’s total revenue in FY19 was $5.9 billion. Of that total, only 3.6% was general revenue appropriated by the State of Texas.

Net patient revenue 77.8%
Restricted grants and contracts, philanthropy 8.8%
State-appropriated general revenue 3.6%
Investment and other non-operating income 6.8%
Other income 2.2%
Auxiliary income 0.8%

MD Anderson generates $28.3 additional dollars for cancer patient care, education and research for each $1 of general revenue, and $40.2 dollars in research support for every $1 in general revenue from the state for research.
Close to 7,000 trainees, including physicians, scientists, nurses and allied health professionals, took part in educational programs at MD Anderson in FY19. The institution’s School of Health Professions awards degrees in 10 bachelor’s programs and two master’s programs in allied health disciplines. In collaboration with the UT Health Science Center at Houston, MD Anderson awards M.S., Ph.D. and M.D./Ph.D. degrees at the MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.

### Education Profile

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical residents, fellows</td>
<td>1,968</td>
</tr>
<tr>
<td>Research trainees</td>
<td>1,600</td>
</tr>
<tr>
<td>Observers, visitors, special programs</td>
<td>876</td>
</tr>
<tr>
<td>Nursing trainees</td>
<td>1,150</td>
</tr>
<tr>
<td>Student programs participants</td>
<td>900</td>
</tr>
<tr>
<td>School of Health Professions students</td>
<td>393</td>
</tr>
<tr>
<td><strong>Total trainees</strong></td>
<td><strong>6,887</strong></td>
</tr>
</tbody>
</table>
Noteworthy

• Through its education programs and network of affiliates, MD Anderson influences the cancer care for one-third of the world’s population.

• MD Anderson is accredited by the Accreditation Council for Graduate Medical Education as a Sponsoring Institution and has maintained Continued Accreditation status for more than 20 years.

• Each year, more than 1,500 clinical residents and fellows come to MD Anderson to receive specialized training in more than 70 residency/fellowship programs that are committed to the investigation and treatment of cancer.

• MD Anderson offers a vast array of nursing training and education opportunities for its own nurses and the health care community outside the institution. These programs include:
  – The Graduate Nurse Residency Program, which provides registered nurses with orientation and transition to practice in five specialty tracks: clinical and research nursing, nursing resource pool, ambulatory treatment center and the operating room.
  – Post Graduate Fellowship in Oncology Nursing, which prepares and trains advanced practice nurses to function as clinical experts in the complex environment of oncology care.

• The American Dental Association and MD Anderson are working together to improve patient outcomes through professional and public education designed to increase human papillomavirus (HPV) vaccinations and tobacco cessation.
MD Anderson continues to set the standard in cancer prevention research and the translation of new knowledge into innovative, multidisciplinary care.

The institution’s Cancer Prevention and Population Sciences division is dedicated to:

• Ending cancer through pioneering research into the roles that biologic, genetic, environmental, economic, behavioral and social factors play in cancer development.

• Investigating various types of interventions to prevent or reduce cancer risk.

• Improving cancer care delivery, safety, availability and affordability.

Through the Duncan Family Institute for Cancer Prevention and Risk Assessment, the division is investing in promising new research directions and integrating basic research and clinical studies to accelerate their translation from the lab to the clinic to the community.

The Lyda Hill Cancer Prevention Center provides cancer risk assessments; screening exams based on genetics, age and gender; and personalized risk-reduction strategies, including lifestyle-based interventions and chemoprevention.
In FY19, there were 48,853 patient visits in the Lyda Hill Cancer Prevention Center.

More than 7,600 patients received tobacco cessation services through the Tobacco Treatment Program in FY19.

Community Relations and Education provided tobacco/vaping prevention education to 24,260 children and teens in FY19.

In an important step toward protecting the health of future generations and reducing the burden of tobacco use in Texas, the Texas Legislature passed Senate Bill 21 in May 2019, raising the minimum legal sale age for all tobacco products from 18 to 21. MD Anderson experts served as clinical and scientific resources on this issue for state legislators.

MD Anderson is home to the only site in Texas accredited by the Council for Tobacco Treatment Training Programs to train health care professionals interested in seeking Tobacco Treatment Specialist (TTS) Training and Certification (CTTS).

Thanks to Eliminate Tobacco Use, a joint initiative of The University of Texas System and MD Anderson, all 14 UT System institutions are tobacco-free. MD Anderson’s EndTobacco™ program, an evidence-based tobacco-control initiative, played an instrumental role in the creation of Eliminate Tobacco Use.

<table>
<thead>
<tr>
<th>Prevention Research Funding FY19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor and designated funds</td>
</tr>
<tr>
<td>Grants and contracts</td>
</tr>
</tbody>
</table>

Noteworthy
• MD Anderson’s Be Well Communities™ is a community approach to cancer prevention and control to promote wellness and reduce modifiable cancer risk factors. MD Anderson leads Be Well™ Baytown — the inaugural Be Well Community — with the support of 16 collaborating organizations focused on the five target health areas of diet, physical activity, preventive care, tobacco control and sun safety.

• With the support of the cancer prevention and control platform, MD Anderson’s HPV-Related Cancers Moon Shot® is working to identify practical solutions and strategies to enhance awareness, improve vaccination rates and ultimately reduce incidence and mortality of HPV-related cancers.

• Underscoring the importance of sharing risks with patients considering lung cancer screening, MD Anderson researchers found that complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated in the community setting.

• MD Anderson became the official cancer center and jersey partner of the Houston Dash, a National Women’s Soccer League (NWSL) team, and continued to serve in the same role for the two-time Major League Soccer (MLS) champion Houston Dynamo. The collaboration with the Dynamo is the first season-long, cause-related jersey partnership in MLS history and the Dash collaboration is the only one of its kind in NWSL history.
At the nation’s No. 1 hospital for cancer care (U.S. News and World Report), almost 22,000 employees are working to advance patient care, research and education. Some of the world’s most recognized researchers and clinicians are part of this elite team that is Making Cancer History®.

Noteworthy

- MD Anderson was ranked No. 17 on Forbes’ “America’s Best Employers for 2019” list, which ranked 500 large employers and 500 mid-size employers. MD Anderson also was included in Forbes’ ranking of “Best Employers for Diversity.”

- Becker’s Healthcare named MD Anderson to its 2019 150 Great Places to Work in Healthcare list.

- For the second year, MD Anderson President Peter WT Pisters, M.D., was named a Top CEO by Glassdoor, a job and recruiting website. He was the second highest-rated leader for hospital systems and the only health care leader in Texas to make the top 100 list.

- MD Anderson was recognized by Military Times as a 2019 Best for Vets employer for the third consecutive year. MD Anderson was the highest health-related organization to make the list in the government and nonprofit sector.
• The Texas Committee for Employer Support of the Guard and Reserve (ESGR) honored MD Anderson as a recipient of the 2019 Pro Patria Award for the institution’s continued support of employees who serve in the National Guard or Military Reserve.

• The American College of Medical Quality (ACMQ) presented its 2019 Institutional Leadership in Quality Award to MD Anderson in FY19, recognizing the institution’s efforts to develop leaders in medical quality management.

• The National Diversity Council’s Healthcare Diversity Week named Carin Hagberg, M.D., chief academic officer and division head, Anesthesiology, Critical Care and Pain Medicine, as a recipient of the Top 25 Women in Healthcare Award in Houston.

• Kim Carstens, a clinical nurse in Radiation Oncology at MD Anderson West Houston, is the recipient of the 2019 Brown Foundation Award for Excellence in Oncology Nursing.

• Sheryl Harris, a nursing assistant in Radiation Oncology at MD Anderson West Houston, received the Julie and Ben Rogers Award for Excellence in Patient Care.

• MD Anderson’s faculty is one of the most esteemed in the nation, including one Nobel Laureate, seven members of the National Academy of Medicine, six National Academy of Sciences members, four American Academy of Arts and Sciences members and 45 American Association for the Advancement of Science fellows.
In addition to the Texas Medical Center campus and research campuses in Bastrop and Smithville, Texas, MD Anderson provides cancer care at several convenient locations throughout Greater Houston. MD Anderson Cancer Network® advances our mission of eliminating cancer by collaborating with community hospitals and health systems to improve the quality of care nationwide.

**Houston-area locations**

- Texas Medical Center
- Katy
- League City
- Sugar Land
- The Woodlands
- Bellaire (imaging and blood work)
- Memorial City (surgery)
- West Houston (imaging and blood work)
- The Woman’s Hospital of Texas (gynecologic cancer care)
- Selected Memorial Hermann locations (breast imaging and diagnostic services)
MD Anderson Cancer Network®

PARTNERS

• Banner MD Anderson Cancer Center (Gilbert, Arizona)
• MD Anderson Cancer Center at Cooper (Camden, New Jersey)
• Baptist MD Anderson Cancer Center (Jacksonville, Florida)
• Scripps MD Anderson Cancer Center (San Diego)
• UT Health San Antonio MD Anderson Cancer Center
• UT Health North Campus Tyler MD Anderson Cancer Center

PARTNER EXTENSIONS

• Banner MD Anderson Cancer Center at North Colorado Medical Center (Greeley, Colorado)
• Banner MD Anderson Cancer Center at McKee Medical Center (Loveland, Colorado)

CERTIFIED MEMBERS

• 15 health systems and hospitals in 12 states

ASSOCIATES

• MD Anderson Cancer Center Madrid
• Vehbi Koc Foundation American Hospital (Istanbul)

AFFILIATES

• MD Anderson Radiation Treatment Center at American Hospital (Istanbul)
• Presbyterian MD Anderson Radiation Treatment Center (Albuquerque, New Mexico)
Mission
The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

Vision
We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science.

We are Making Cancer History®.

Core Values
Caring: By our words and actions, we create a caring environment for everyone.

Integrity: We work together to merit the trust of our colleagues and those we serve.

Discovery: We embrace creativity and seek new knowledge.